Quick Answer
TriSalus Life Sciences, Inc. reported R&D Expense of $14.96 million for fiscal year 2025.
TriSalus Life Sciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $14.96M | -15.4% |
| 2024 | $17.69M | -40.7% |
| 2023 | $29.84M | +39.7% |
| 2022 | $21.36M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.18M | +22.7% | +31.9% |
| June 30, 2025 | $3.92M | -15.9% | +19.0% |
| March 31, 2025 | $3.30M | -43.6% | -21.9% |
| September 30, 2024 | $4.22M | -55.6% | -9.6% |
| June 30, 2024 | $4.67M | -32.2% | -20.2% |
| March 31, 2024 | $5.84M | +3.6% | -38.5% |
| September 30, 2023 | $9.51M | +97.7% | +38.0% |
| June 30, 2023 | $6.89M | — | +22.0% |
- TriSalus Life Sciences, Inc. showed a decrease of -15.4% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, TriSalus Life Sciences, Inc.’s r&d expense has declined by 29.9% (from $21.36 million to $14.96 million).
- The most recent figure is from TriSalus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: